Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

RemeGen Out-Licenses HER-2 Candidate to Seagen in $2.6 Billion Agreement

publication date: Aug 10, 2021

Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company previously known as Seattle Genetics, will pay $200 million upfront and up to $2.4 billion in milestones. The candidate, disitamab vedotin, combines Seagen's drug-linker technology with RemeGen’s novel HER2 antibody. The candidate has shown promising activity in trials involving several solid tumor types associated with HER-2, including urothelial, gastric and breast cancers. More details....

Stock Symbols: (HK: 9995) (NSDQ: SGEN)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital